Rasonque-chemotherapy combination shows 60.7% response rate in pancreatic cancer trial
RVMD•Revolution Medicines reported a 60.7% response rate with RASONQUE combined with chemotherapy in a trial of previously untreated metastatic pancreatic cancer.
1. Trial results
Updated Phase 1/2 results showed durable tumor responses with RASONQUE combined with chemotherapy in previously untreated metastatic pancreatic cancer. The company said the combination's safety profile remained consistent with previously observed profiles for the treatments, and the findings support the ongoing Phase 3 RASolute 303 trial.




